CATL Shares Fall as Hungary Plant Faces Safety Halt 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Milei Threatens Falkland Oil Firms With Sanctions 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Add as a preferred source on Google
March 2, 2018 – XYMOGEN, Inc., a leading manufacturer of medical foods and dietary supplements, announced today that is has prevailed in a lawsuit with Thorne Research. On February 20, 2018, after a six-day trial, a jury in the United States District Court for the District of Utah ruled for XYMOGEN. The jury found that XYMOGEN’s proprietary and highly-absorbed CoQMax product was actually invented by a chemist from XYMOGEN’s manufacturer thereby invalidating Thorne’s patent on their product.
|
|||
“I am extremely pleased that the jury saw fit to discredit Thorne’s claims and invalidate their patent”, said Brian Blackburn, XYMOGEN’s Founder and CEO. “Claiming a patent on an invention by a third-party misleads the public, and I hope the jury’s verdict will deter others from similar practices.”
About XYMOGEN:
To learn more about XYMOGEN, a family-owned, health sciences company, and its formulas, distribution, and community involvement, visit XYMOGEN.com, email [email protected], or call 800-647-6100. XYMOPrint, a full-service digital printer and design studio, XYMOGEN LOGISTICS, a third-party fulfillment, warehousing, and shipping provider; and PharmaceutiX Medical Foods are all subsidiaries of XYMOGEN.
6900 Kingesporte Parkway
Orlando, Fl
Tel: 800-647-6100
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3a48371c-6283-4c53-afa1-bb7a889b35d1
Meghan Blackburn XYMOGEN 800-647-6100, Ext. 8875 [email protected]
